Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. (Q53185271)

From Wikidata

Jump to navigation Jump to search

scientific article published on 2 February 2016

Language	Label	Description	Also known as
English	Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution.	scientific article published on 2 February 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

Radical cystectomy

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

6

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

14

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

Alberto Briganti

12

object named as

Alberto Briganti

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

Francesco Montorsi

11

object named as

Francesco Montorsi

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

Shahrokh Shariat

9

object named as

Shahrokh F Shariat

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

10

object named as

Andrea Salonia

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

Paolo Dell'Oglio

4

object named as

Paolo Dell׳Oglio

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

Giorgio Gandaglia

5

object named as

Giorgio Gandaglia

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

Martina Sofia Rossi

3

object named as

Martina Sofia Rossi

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

author name string

Marco Bianchi

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

Agostino Mattei

7

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

Rocco Damiano

8

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

Renzo Colombo

13

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

publication date

2 February 2016

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

Urologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

34

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

6

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

256.e7-256.e13

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

Effect of Allogeneic Intraoperative Blood Transfusion on Survival in Patients Treated With Radical Cystectomy for Nonmetastatic Bladder Cancer: Results From a Single High-Volume Institution

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

The effect of intra- and postoperative allogenic blood transfusion on patients' survival undergoing radical cystectomy for urothelial carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

A new prognostic model for cancer-specific survival after radical cystectomy including pretreatment thrombocytosis and standard pathological risk factors

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

The prognostic value of hematological and systemic inflammatory disorders in invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

Transfusion-related immunomodulation (TRIM): an update

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

Cancer biology, analgesics, and anaesthetics: is there a link?

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

Do blood groups have effect on prognosis of patients undergoing radical cystectomy?

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

ABO blood group and the risk of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

Role of blood groups as prognostic factors in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

Perioperative blood transfusion and radical cystectomy: does timing of transfusion affect bladder cancer mortality?

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

Genotypic and phenotypic characterization of the histoblood group ABO(H) in primary bladder tumors

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

Possible mechanisms of allogeneic blood transfusion-associated postoperative infection

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

Improvement of Kidney-Graft Survival with Increased Numbers of Blood Transfusions

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

DNA methylation of the ABO promoter underlies loss of ABO allelic expression in a significant proportion of leukemic patients

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

Genetic and epigenetic alterations of the blood group ABO gene in oral squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.12.016

7 January 2021

Identifiers

10.1016/J.UROLONC.2015.12.016

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26850780

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53185271&oldid=1739653365"